Table 2:

%ddcfDNA for primary and secondary endpoints from Day 28 onwards

Clinical endpoint		Number of events	Subjects with events	Median %ddcfDNA	%ddcfDNA interquartile range (%)	p-value
Controls (ACR0, ACR1, pAMR0)		1072	165	0.03	0.01 – 0.14	-
Acute rejection (AR)		49	31	0.38	0.31 – 0.83	<0.001*
ACR
	Grade 0	618	165	0.02	0.01 – 0.13
	Grade 1	454	165	0.04	0.01 – 0.17	0.023†
	Grade ≥2	28	21	0.34	0.28 – 0.72	<0.001†
AMR
	pAMR0	1072	165	0.03	0.01 – 0.14
	pAMR1	14	9	0.63	0.34 – 0.77	<0.001‡
	pAMR2	11	9	1.68	0.49 – 2.79	<0.001‡
Allograft dysfunction
	None	866	165	0.02	0.01 – 0.12
	mild	168	83	0.06	0.01 – 0.27	0.068‖
	moderate	62	49	0.19	0.01 – 0.60	0.018‖
	severe	38	28	0.32	0.05 – 0.47	<0.001‖

p-values obtained using generalized estimating equation approach to compare groups accounting for repeated measures at individual subject level.

^{* =}p-value comparing AR to control

^†p-value comparing ACR grades 1 and 2 to ACR grade 0

^‡p-values comparing pAMR grades 1 and 2 to grade 0

^‖p-values comparing severities of allograft dysfunction to no allograft dysfunction. Subjects may have more than 1 category of endpoints.